Dicot Pharma informs that two additional patents are in the process of being approved in USA
Uppsala, Sweden, October 14, 2024. Dicot Pharma announces today that the company has received Notice of Allowance for two US patent applications from the US Patent and Trademark Office (USPTO). These include, among other things, the active substance in LIB-01. A Notice of Allowance means that the USPTO intends to grant a patent once certain formal steps have been taken.Recently, Dicot Pharma announced that it received a Notice of Allowance from the USPTO regarding a patent application (No. 18/496,049) covering key steps in the manufacture of the active substance in LIB-01. Today, the